Antiphospholipid Antibodies in Patients with Coronary Artery Disease

:  Antiphospholipid antibodies (aPL) have been implicated in the pathogenesis of coronary artery disease (CAD). We evaluated the presence of aPL in patients with chest pain/acute coronary syndromes (ACS) to determine if aPL were associated with the presence and severity of CAD, adverse outcomes, and...

Full description

Saved in:
Bibliographic Details
Published in:Annals of the New York Academy of Sciences 2007-06, Vol.1108 (1), p.466-474
Main Authors: GRECO, TOM P., CONTI-KELLY, ANN MARIE, MATSUURA, EIJI, GRECO Jr, TOM, DIER, KEN J., SVANAS, GREGORY, DOYLE, ROBIN, LOPEZ, LUIS R.
Format: Article
Language:English
Subjects:
acute coronary syndromes
antiphospholipid syndrome
cardiac risk
β2GP1 antibodies
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary::  Antiphospholipid antibodies (aPL) have been implicated in the pathogenesis of coronary artery disease (CAD). We evaluated the presence of aPL in patients with chest pain/acute coronary syndromes (ACS) to determine if aPL were associated with the presence and severity of CAD, adverse outcomes, and other coronary risk factors. Patients with chest pain/ACS were evaluated for aPL prior to diagnostic and therapeutic investigations. Coronary angiograms were graded according to the severity of disease. Risk factors, including family histories, were assessed and patients were followed for adverse outcomes. To date, 232 patients (116 M, 116 F, mean age 63 years) with a mean follow‐up of 9 months were studied. Thirty‐seven percent (86/232) were positive for one or more aPL. More women, 49/86 (57%), were aPL positive versus men, 37/86 (43%). The presence of aPL appeared associated with both presence and severity of CAD (P= 0.176 women; P= 0.163 men). In patients undergoing procedures (angioplasty, stent, bypass), aPL was significantly associated with both an increase in adverse cardiac outcomes (P= 0.045) and extracardiac thrombotic events (P= 0.033). Anti‐β2 glycoprotein‐1 (aβ2GP1) was the most frequent aPL, occurring in 68.5% of aPL‐positive patients with CAD. Anticardiolipin antibody (aCL) occurred in only 7.4%. IgM isotypes were the most frequent for all categories of aPL (range 55–90%). Family history of antiphospholipid syndrome (APS)‐related events was more significant in aPL‐positive than aPL‐negative individuals (P= 0.027).
ISSN:0077-8923
1749-6632
DOI:10.1196/annals.1422.049